Evidence map›Paper›PMID 36148360›Full record

ArticleFrontiers in public health2022

Case report: A 9-year systematic treatment failure of a pulmonary tuberculosis patient.

Hui Jiang, Chendi Zhu, Liyi Qin, Xiaoguang Wu, Jinfeng Yin, Yijia Guo, Huan Ma, Junnan Jia, Fengmin Huo, Yi Xue and 2 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Hui JiangBeijing Chest Hospital, Capital Medical University, Beijing, China.
Chendi ZhuBeijing Chest Hospital, Capital Medical University, Beijing, China.
Liyi QinBeijing Chest Hospital, Capital Medical University, Beijing, China.
Xiaoguang WuBeijing Chest Hospital, Capital Medical University, Beijing, China.
Jinfeng YinBeijing Chest Hospital, Capital Medical University, Beijing, China.
Yijia GuoBeijing Chest Hospital, Capital Medical University, Beijing, China.
Huan MaSchool of Public Health, Wenzhou Medical University, Wenzhou, China.
Junnan JiaBeijing Chest Hospital, Capital Medical University, Beijing, China.
Fengmin HuoBeijing Chest Hospital, Capital Medical University, Beijing, China.
Yi XueBeijing Chest Hospital, Capital Medical University, Beijing, China.
Mengqiu GaoBeijing Chest Hospital, Capital Medical University, Beijing, China.
Weimin LiBeijing Chest Hospital, Capital Medical University, Beijing, China.
Beijing Chest Hospital · CNCapital Medical University · CNWenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To explore the reasons of failure in a case of pulmonary tuberculosis (PTB) after 9 years systematic treatment. Methods: We extracted the patients' treatment history, drug susceptibility testing (DST), Computed tomography (CT) images, and sequenced the isolated strains by whole gene sequencing (WGS). Results: Although most results of the phenotypical DSTs were consistent with the genotype DST, the occurrence of gene resistance to amikacin (AMK), capreomycin (CAP), moxifloxacin (MFX) was earlier than the phenotypical DST. Based on the continuously reversed results of phenotypical DSTs, CT images in different stages and WGS, it can be confirmed that the patient was infected with two different strains of Mycobacterium tuberculosis (M.TB). Moreover, severe cavities may be another factor leading to treatment failure. Conclusion: Given the suggestive effect of genotype DST is earlier than the phenotypical DST, so genotype DST can play a better guiding role in patients with MDR-TB. Additionally, for patients who have not been cured for a long time, medication should be more cautious and the role of WGS in drug resistance surveillance should be fully utilized.

Indexed as

Mycobacterium tuberculosisTuberculosis, PulmonaryAmikacinAntitubercular AgentsCapreomycinDrug Resistance, Multiple, BacterialHumansMicrobial Sensitivity TestsMoxifloxacinTreatment FailureAmikacinAntitubercular AgentsCapreomycinMoxifloxacincomputed tomography-three dimensionalmultidrug resistancetreatment failuretuberculosiswhole genome sequencing

Identifiers

PMID36148360
PMCPMC9487995
OpenAlexW4294771027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.